A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor (NERI), in the treatment of major depression

Trial Profile

A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor (NERI), in the treatment of major depression

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2008

At a glance

  • Drugs Edivoxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Apr 2008 Actual number patients enrolled was 470.
    • 24 Apr 2008 Actual completion date for this trial is 1 March 2008.
    • 24 Apr 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top